Kimberley S Mak1, Justin F Gainor1, Andrzej Niemierko1, Kevin S Oh1, Henning Willers1, Noah C Choi1, Jay S Loeffler1, Lecia V Sequist1, Alice T Shaw1, Helen A Shih1. 1. Harvard Radiation Oncology Program, Massachusetts General Hospital, Boston, Massachusetts (K.S.M.); Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts (J.F.G.); Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts (A.N., K.S.O., H.W., N.C.C., J.S.L., H.A.S.); Massachusetts General Hospital Cancer Center, Boston, Massachusetts (L.V.S., A.T.S.).
Abstract
BACKGROUND: We determined the impact of genetic alterations in EGFR, ALK, or KRAS on survival after radiotherapy for brain metastases in non-small cell lung cancer (NSCLC). METHODS: Of 172 genotyped NSCLC patients treated with radiotherapy for brain metastases in 2005-2012, 54 had cancers with EGFR mutations, 12 had ALK rearrangements, 38 had KRAS mutations, and 68 were wild-type (WT). Overall survival (OS) was determined. RESULTS: Median follow-up was 8.6 months. Median OS was 13.6 months for patients with EGFR mutations and 26.3 months for patients with ALK rearrangements, in contrast to 5.7 months for KRAS-mutant patients and 5.5 months for WT patients (P = .001). On multivariate analysis, adjusting for receipt of targeted therapy after cranial radiotherapy, ALK rearrangements were associated with improved OS (HR, 0.31; 95% CI, 0.13-0.74; P = .008). EGFR mutations were not significantly associated with improved OS on multivariate analysis (HR, 0.71; 95% CI, 0.37-1.38; P = .3). KRAS mutations were also not associated with improved OS (HR, 0.93; 95% CI, 0.59-1.47; P = .8). Receipt of targeted therapy after cranial radiotherapy was independently associated with improved OS (HR, 0.30; 95% CI, 0.17-0.54; P < .001). Receipt of chemotherapy after cranial radiotherapy, number of brain metastases, extracranial metastases, age, and performance status were also associated with OS. CONCLUSIONS: NSCLC patients with genetic alterations in ALK have improved survival outcomes after radiotherapy for brain metastases compared with EGFR, KRAS, or WT. Subsequent receipt of targeted therapy was associated with additional improvement in OS.
BACKGROUND: We determined the impact of genetic alterations in EGFR, ALK, or KRAS on survival after radiotherapy for brain metastases in non-small cell lung cancer (NSCLC). METHODS: Of 172 genotyped NSCLCpatients treated with radiotherapy for brain metastases in 2005-2012, 54 had cancers with EGFR mutations, 12 had ALK rearrangements, 38 had KRAS mutations, and 68 were wild-type (WT). Overall survival (OS) was determined. RESULTS: Median follow-up was 8.6 months. Median OS was 13.6 months for patients with EGFR mutations and 26.3 months for patients with ALK rearrangements, in contrast to 5.7 months for KRAS-mutant patients and 5.5 months for WT patients (P = .001). On multivariate analysis, adjusting for receipt of targeted therapy after cranial radiotherapy, ALK rearrangements were associated with improved OS (HR, 0.31; 95% CI, 0.13-0.74; P = .008). EGFR mutations were not significantly associated with improved OS on multivariate analysis (HR, 0.71; 95% CI, 0.37-1.38; P = .3). KRAS mutations were also not associated with improved OS (HR, 0.93; 95% CI, 0.59-1.47; P = .8). Receipt of targeted therapy after cranial radiotherapy was independently associated with improved OS (HR, 0.30; 95% CI, 0.17-0.54; P < .001). Receipt of chemotherapy after cranial radiotherapy, number of brain metastases, extracranial metastases, age, and performance status were also associated with OS. CONCLUSIONS:NSCLCpatients with genetic alterations in ALK have improved survival outcomes after radiotherapy for brain metastases compared with EGFR, KRAS, or WT. Subsequent receipt of targeted therapy was associated with additional improvement in OS.
Authors: Paul W Sperduto; Brian Berkey; Laurie E Gaspar; Minesh Mehta; Walter Curran Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-10 Impact factor: 7.038
Authors: April F Eichler; Kristopher T Kahle; Daphne L Wang; Victoria A Joshi; Henning Willers; Jeffrey A Engelman; Thomas J Lynch; Lecia V Sequist Journal: Neuro Oncol Date: 2010-07-13 Impact factor: 12.300
Authors: David A Eberhard; Bruce E Johnson; Lukas C Amler; Audrey D Goddard; Sherry L Heldens; Roy S Herbst; William L Ince; Pasi A Jänne; Thomas Januario; David H Johnson; Pam Klein; Vincent A Miller; Michael A Ostland; David A Ramies; Dragan Sebisanovic; Jeremy A Stinson; Yu R Zhang; Somasekar Seshagiri; Kenneth J Hillan Journal: J Clin Oncol Date: 2005-07-25 Impact factor: 44.544
Authors: Alice T Shaw; Beow Y Yeap; Mari Mino-Kenudson; Subba R Digumarthy; Daniel B Costa; Rebecca S Heist; Benjamin Solomon; Hannah Stubbs; Sonal Admane; Ultan McDermott; Jeffrey Settleman; Susumu Kobayashi; Eugene J Mark; Scott J Rodig; Lucian R Chirieac; Eunice L Kwak; Thomas J Lynch; A John Iafrate Journal: J Clin Oncol Date: 2009-08-10 Impact factor: 44.544
Authors: P Keohavong; M A DeMichele; A C Melacrinos; R J Landreneau; R J Weyant; J M Siegfried Journal: Clin Cancer Res Date: 1996-02 Impact factor: 12.531
Authors: Dora Dias-Santagata; Sara Akhavanfard; Serena S David; Kathy Vernovsky; Georgiana Kuhlmann; Susan L Boisvert; Hannah Stubbs; Ultan McDermott; Jeffrey Settleman; Eunice L Kwak; Jeffrey W Clark; Steven J Isakoff; Lecia V Sequist; Jeffrey A Engelman; Thomas J Lynch; Daniel A Haber; David N Louis; Leif W Ellisen; Darrell R Borger; A John Iafrate Journal: EMBO Mol Med Date: 2010-05 Impact factor: 12.137
Authors: Suresh K Balasubramanian; Mayur Sharma; Vyshak A Venur; Philipp Schmitt; Rupesh Kotecha; Samuel T Chao; John H Suh; Lilyana Angelov; Alireza M Mohammadi; Michael A Vogelbaum; Gene H Barnett; Xuefei Jia; Nathan A Pennell; Manmeet S Ahluwalia Journal: Neuro Oncol Date: 2020-02-20 Impact factor: 12.300
Authors: Paul W Sperduto; T Jonathan Yang; Kathryn Beal; Hubert Pan; Paul D Brown; Ananta Bangdiwala; Ryan Shanley; Norman Yeh; Laurie E Gaspar; Steve Braunstein; Penny Sneed; John Boyle; John P Kirkpatrick; Kimberley S Mak; Helen A Shih; Alex Engelman; David Roberge; Nils D Arvold; Brian Alexander; Mark M Awad; Joseph Contessa; Veronica Chiang; John Hardie; Daniel Ma; Emil Lou; William Sperduto; Minesh P Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2016-06-14 Impact factor: 7.038
Authors: Tony J C Wang; Shumaila Saad; Yasir H Qureshi; Ashish Jani; Tavish Nanda; Andrew M Yaeh; Tzlil Rozenblat; Michael B Sisti; Jeffrey N Bruce; Guy M McKhann; Jeraldine Lesser; Balazs Halmos; Mark B Stoopler; Andrew B Lassman; Simon K Cheng; Steven R Isaacson Journal: Neuro Oncol Date: 2015-04-24 Impact factor: 12.300